ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
When money talks: Judging risk and coercion in high-paying clinical trials
dc.contributor.author | Leuker, Christina | |
dc.contributor.author | Samartzidis, Lasare | |
dc.contributor.author | Hertwig, Ralph | |
dc.contributor.author | Pleskac, Timothy J. | |
dc.date.accessioned | 2020-06-16T18:25:49Z | |
dc.date.available | 2020-06-16T18:25:49Z | |
dc.date.issued | 2020-01-31 | |
dc.identifier.citation | Leuker, C., Samartzidis, L., Hertwig, R., & Pleskac, T. J. (2020). When money talks: Judging risk and coercion in high-paying clinical trials. PloS one, 15(1), e0227898. https://doi.org/10.1371/journal.pone.0227898 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/30509 | |
dc.description | This work is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.description.abstract | Millions of volunteers take part in clinical trials every year. This is unsurprising, given that clinical trials are often much more lucrative than other types of unskilled work. When clinical trials offer very high pay, however, some people consider them repugnant. To understand why, we asked 1,428 respondents to evaluate a hypothetical medical trial for a new Ebola vaccine offering three different payment amounts. Some respondents (27%) used very high pay (£10,000) as a cue to infer the potential risks the clinical trial posed. These respondents were also concerned that offering £10,000 was coercive— simply too profitable to pass up. Both perceived risk and coercion in high-paying clinical trials shape how people evaluate these trials. This result was robust within and between respondents. The link between risk and repugnance may generalize to other markets in which parties are partially remunerated for the risk they take and contributes to a more complete understanding of why some market transactions appear repugnant. | en_US |
dc.publisher | Public Library of Science | en_US |
dc.rights | © 2020 Leuker et al. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.title | When money talks: Judging risk and coercion in high-paying clinical trials | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Pleskac, Timothy J. | |
kusw.kudepartment | Psychology | en_US |
dc.identifier.doi | 10.1371/journal.pone.0227898 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-2337-3785 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC6994245 | en_US |
dc.rights.accessrights | openAccess | en_US |